AKT1 and schizophrenia: This hypothesis is supported by a recent study demonstrating that lipoteichoic acid treatment down-regulates the expression of phospho-protein kinase B (PKB/AKT) and phospho- glycogen synthase kinase-3α/β, which are up-regulated in a Tlr2-deficient mouse model of schizophrenia (Park et al., 2015).